Document Type : Original Article
Authors
- . Elham Faghihimani 1
- . Masoud Amini 1
- . Atoosa Adibi 2
- . Zohreh Naderi 3
- . Ali Toghiani 4
- . Peyman Adibi 5
1 Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Young Researchers Club, Islamic Azad University, Najafabad Branch, Isfahan, Iran
5 Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Nearly two-third of the patients with type 2 diabetes have degrees of fatty liver;
this may induce some side effects in them. This study aimed to find effect of salsalate on
treatment of steatohepatitis and correlation of fatty liver with metabolic syndrome in the
setting of impaired glucose metabolism.
Methods: In a double-blind randomized trial within two distinct groups, i.e., recently
diagnosed diabetics and prediabetic cases allocated in two arms of the intervention to
receive 3 g salsalate or placebo. All cases underwent glucose and lipid level studies and
liver ultrasound study.
Findings: Out of 46 patients with diabetes, 34 (74%) had fatty liver in ultrasound; this
ratio was 75% in 113 prediabetic cases. Relative frequency of fatty liver stages did not differ
between diabetics and prediabetics. Within diabetics, mean aspartate aminotransferase
(AST) level of fatty liver cases (23 ± 7 IU/dl) was higher than others (18 ± 3 IU/dl) (P <
0.05). Changes in transaminase levels following intervention did not significantly differ,
comparing drug and placebo arms in two subgroups.
Conclusion: According to the findings, if diabetes could be assumed as the logical
consequence of prediabetic state, it seems that fatty liver did develop before this
preliminary status. In this study, salsalate could not change biochemical markers of fatty
liver significantly.
Keywords
- El-Koofy NM, Anwar GM, El-Raziky MS, El-Hennawy AM,
El-Mougy FM, El-Karaksy HM, et al. The association of
metabolic syndrome, insulin resistance and non-alcoholic
fatty liver disease in overweight/obese children. Saudi J
Gastroenterol 2012;18:44-9.
2. Moscatiello S, Di Luzio R, Sasdelli AS, Marchesini G. Managing
the combination of nonalcoholic fatty liver disease and metabolic
syndrome. Expert Opin Pharmacother 2011;12:2657-72.
3. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes
mellitus. Curr Opin Endocrinol Diabetes Obes 2009;16:141-9. - 4. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of
cirrhosis and hepatocellular carcinoma in type 2 diabetes.
Curr Diab Rep 2007;7:175-80.
5. Targher G, Marra F, Marchesini G. Increased risk of
cardiovascular disease in non-alcoholic fatty liver disease:
causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L,
Holmqvist M, Bodemar G, et al. Long-term follow-up of
patients with NAFLD and elevated liver enzymes. Hepatology
2006;44:865-73.
7. Tataranni PA, Ortega E. A burning question: Does an
adipokine-induced activation of the immune system mediate
the effect of overnutrition on type 2 diabetes? Diabetes
2005;54:917-27.
8. Hotamisligil GS. Inflammation and metabolic disorders.
Nature 2006;444:860-7.
9. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin
resistance. J Clin Invest 2006;116:1793-801.
10. American Diabetes Association. Diagnosis and classification
of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62-7.
11. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J,
Cheung O, et al. A lipidomic analysis of nonalcoholic fatty
liver disease. Hepatology 2007;46:1081-90.
12. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A,
Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty
liver disease with normal aminotransferase levels: A role for
insulin resistance and diabetes. Hepatology 2008;48:792-8.
13. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use
of salsalate to target inflammation in the treatment of insulin
resistance and type 2 diabetes. Clin Transl Sci 2008;1:36-43.
14. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, HansonRL, et al.
The effect of salsalate on insulin action and glucose tolerance
in obese nondiabetic patients: Results of a randomised doubleblind placebo-controlled study. Diabetologia 2009;52:385-93.
15. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate
improves glycemia and inflammatory parameters in obese
young adults. Diabetes Care 2008;31:289-94.
)